文献速递产科母胎医学

妊娠前90天内父亲暴露于甲氨蝶呤后不良妊娠结局的风险

Risk of Adverse Pregnancy Outcome After Paternal Exposure to Methotrexate Within 90 Days Before Pregnancy.
PubMed 文献 · Obstet Gynecol · 2017-01-01

丹麦全国注册研究纳入1997至2011年849676例已知父权的活产儿,其中127例父亲在妊娠前90天内暴露于甲氨蝶呤。暴露组重大畸形4例(3.2%),非暴露组28814例(3.4%),校正后OR为1.01(95%CI 0.37-2.74);暴露组无死产,非暴露组死产2541例(0.3%),早产校正OR为1.31(95%CI 0.66-2.59)。结论认为父亲妊娠前90天内甲氨蝶呤暴露与重大畸形、死产或早产无关。

要点

  • 父亲妊娠前90天内甲氨蝶呤暴露与重大先天畸形无显著关联(校正OR 1.01,95%CI 0.37-2.74)。
  • 暴露组无死产,非暴露组死产2541例(0.3%),早产风险无显著增加(校正OR 1.31,95%CI 0.66-2.59)。
  • 作者认为妊娠前父亲甲氨蝶呤暴露不应引起主要担忧,并建议据此修改多国推荐。

核心结论

  • 父亲在妊娠前90天内暴露于甲氨蝶呤与重大先天畸形、死产或早产无关联。
  • 现有数据提示妊娠前父亲甲氨蝶呤暴露不应引起主要担忧,多国推荐应据此修改。

研究设计与样本

  • 丹麦全国注册研究,纳入1997至2011年丹麦医学出生登记中全部活产儿,共849676例已知父权的活产儿。
  • 甲氨蝶呤暴露父亲从全国处方登记中识别,父权、活产、死产及先天畸形出院诊断从全国医院登记中识别。

主要发现

  • 暴露组127例活产儿中重大畸形4例(3.2%),非暴露组28814例(3.4%);暴露组相对非暴露组重大先天畸形的OR为0.93(95%CI 0.34-2.51),校正出生年份、母亲年龄、教育年限、家庭收入和产次后校正OR为1.01(95%CI 0.37-2.74)。
  • 暴露组无死产,非暴露组死产2541例(0.3%)。
  • 暴露组子代早产风险无显著增加,校正OR为1.31(95%CI 0.66-2.59)。

临床怎么用

  • 作者认为妊娠前父亲甲氨蝶呤暴露不应引起主要担忧,并建议据此修改多国推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To study the association between paternal exposure to methotrexate within the 90-day period before pregnancy and congenital malformations and stillbirth in the offspring. METHODS: We conducted a nationwide register study. Our cohort consisted of all live births in Denmark between 1997 and 2011 identified from the Medical Birth Registry. Methotrexate-exposed fathers were identified from the National Prescription Registry. From the national Hospital Registry we identified paternity, live births, and stillbirths as well as discharge diagnoses on congenital malformations. RESULTS: We identified 849,676 live births with known paternity. There were 127 live births of methotrexate-exposed fathers. Of these, four (3.2%) had major malformations compared with 28,814 (3.4%) of the unexposed. The odds ratio (OR) for major congenital malformation among exposed fathers compared with unexposed was 0.93 (95% confidence interval [CI] 0.34-2.51) and when adjusted for year of birth, maternal age, educational length, household income, and parity, the adjusted OR was 1.01 (95% CI 0.37-2.74). There were no stillbirths in the methotrexate-exposed group compared with 2,541 (0.3%) in the unexposed group and no increased risk of preterm birth (adjusted OR 1.31, 95% CI 0.66-2.59) among the children from exposed fathers. CONCLUSION: We found no association between paternal exposure to methotrexate within 90 days before pregnancy and congenital malformations, stillbirths, or preterm birth. Available data suggest that prepregnancy paternal methotrexate exposure should not be of major concern. Multinational recommendations should be changed accordingly.

来源:Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Eck LK, Jensen TB, Mastrogiannis D, et al. Risk of Adverse Pregnancy Outcome After Paternal Exposure to Methotrexate Within 90 Days Before Pregnancy. Obstet Gynecol. 2017. PMID: 28277353. doi:10.1097/AOG.0000000000001936

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。